Affordable Access

O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.

Authors
  • Batts, Eric D
  • Maisel, Christopher
  • Kane, Donna
  • Liu, Lili
  • Fu, Pingfu
  • O'Brien, Timothy
  • Remick, Scot
  • Bahlis, Nizar
  • Gerson, Stanton L
Type
Published Article
Journal
Cancer chemotherapy and pharmacology
Publication Date
Aug 01, 2007
Volume
60
Issue
3
Pages
415–421
Identifiers
PMID: 17354015
Source
Medline
License
Unknown

Abstract

Chemotherapy utilizing the MGMT inhibitor O6-benzylguanine and BCNU results in inhibition of MGMT activity in malignant plasma cells and produces meaningful responses in a modest proportion of patients with multiple myeloma. Hematologic toxicity with this regimen is significant and dose-limiting.

Report this publication

Statistics

Seen <100 times